Eton Pharmaceuticals officer proposes $236K share sale

Available on EDGAR 11/10/2026 - 05:05 PM EST Accepted by SEC EDGAR 11/10/2026 - 05:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. officer Ipek Erdogan-Trinkaus is identified in a notice of a proposed sale of 3,500 common shares, with an approximate sale date of November 10, 2026, and an aggregate market value of $235,937.31. The shares were acquired from the issuer as a grant on January 12, 2026. Raymond James & Associates, Inc. is named as broker. Rashida Mitchell signed as the broker’s duly authorized representative and attorney-in-fact for Ipek Erdogan-Trinkaus.

Key Figures

Shares proposed for sale: 3,500 common shares Aggregate Market Value: $235,937.31 Shares outstanding: 282,889,941 shares

3 metrics

Shares proposed for sale 3,500 common shares Approximate sale date: November 10, 2026

Aggregate Market Value $235,937.31 For the shares listed for sale

Shares outstanding 282,889,941 shares Issuer share count reported in the notice

Key Terms

Aggregate Market Value, Number of Shares or Other Units Outstanding, Attorney-in-fact

3 terms

Aggregate Market Value financial

"Aggregate Market Value | 235937.31"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Number of Shares or Other Units Outstanding financial

"Number of Shares or Other Units Outstanding | 282889941"

Attorney-in-fact regulatory

"as attorney-in-fact for Ipek Erdogan-Trinkaus"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ETON shares does officer Ipek Erdogan-Trinkaus plan to sell?

The notice lists 3,500 common shares for a proposed sale, with an approximate sale date of November 10, 2026 and an aggregate market value of $235,937.31.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002047026
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	Erdogan-Trinkaus Ipek
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, FL 33716	3500	235937.31	282889941	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	GRANT	ISSUER			3500	01/12/2026	GRANT

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Ipek Erdogan-Trinkaus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)